BeiGene
China's largest global biotech company focused on innovative oncology medicines
公司概况
BeiGene is a global biotechnology company headquartered in China that is focused on developing innovative and affordable medicines for cancer patients worldwide. The company's BTK inhibitor Brukinsa has become one of the best-selling cancer drugs globally, and BeiGene has built a commercial presence in over 40 countries. BeiGene represents China's most successful biotech globalization story.
为什么关注这家公司
BeiGene has shattered the perception that Chinese biotech companies cannot compete globally, with Brukinsa becoming a blockbuster drug in the US and European markets.
核心关注领域
同行业公司
Biocon
India's largest biopharmaceutical company and global biosimilars leader
Celltrion
South Korea's leading biosimilar manufacturer challenging global pharma giants
Daiichi Sankyo
Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)
Doctor Anywhere
Southeast Asia's leading omnichannel healthcare platform
Halodoc
Indonesia's leading telehealth and health-tech platform
Healius
Australia's second-largest private pathology and imaging provider
信号活动概览
信号时间线
1 条当该公司有新信号时，立即收到通知。